| 516.74 -2.35 (-0.45%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 661.29 | 1-year : | 772.39 |
| Resists | First : | 566.17 | Second : | 661.29 |
| Pivot price | 516.73 |
|||
| Supports | First : | 492.53 | Second : | 447.01 |
| MAs | MA(5) : | 525.04 |
MA(20) : | 517.42 |
| MA(100) : | 518.35 |
MA(250) : | 497.72 |
|
| MACD | MACD : | -0.6 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 77.3 |
D(3) : | 78.9 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 615 | Low : | 393.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MDGL ] has closed below upper band by 50.0%. Bollinger Bands are 17.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 531.31 - 534.63 | 534.63 - 536.97 |
| Low: | 506.81 - 510.93 | 510.93 - 513.84 |
| Close: | 511.35 - 517.36 | 517.36 - 521.6 |
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Fri, 21 Aug 2026
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Fri, 21 Aug 2026
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Fresh Patents For Liver Drug - Stocktwits
Thu, 20 Aug 2026
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - Stock Titan
Thu, 20 Aug 2026
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - Stock Titan
Thu, 20 Aug 2026
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Wed, 19 Aug 2026
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 23 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 5.8 (%) |
| Held by Institutions | 104 (%) |
| Shares Short | 2,060 (K) |
| Shares Short P.Month | 3,780 (K) |
| EPS | -14.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.68 |
| Profit Margin | -25.4 % |
| Operating Margin | -15.5 % |
| Return on Assets (ttm) | -17.9 % |
| Return on Equity (ttm) | -53.4 % |
| Qtrly Rev. Growth | 71.1 % |
| Gross Profit (p.s.) | 50.64 |
| Sales Per Share | 55.41 |
| EBITDA (p.s.) | -13.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -198 (M) |
| Levered Free Cash Flow | -80 (M) |
| PE Ratio | -36.89 |
| PEG Ratio | 0 |
| Price to Book value | 22.78 |
| Price to Sales | 9.32 |
| Price to Cash Flow | -60.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|